Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT00540007Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2007
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in classical Hodgkin lymphoma (cHL) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Objective Overall Response Rate at 3.5 years. Started Sep 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT00540007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00540007.